Search Results - "Cohen, R B"

Being mindful of our insomnia can get us to sleep? - Mindfulness aproach to sleep disorders by Cohen, R. B., Pereira, I. M., Marguilho, M. G., Sousa, M. C., Ferreira, B. V.

“…Introduction Sleep disorders (e.g., insomnia) are extremely prevalent in our population and are intimately associated with distress and productivity…”
Get full text

Suicidal ideation in older people, a public health matter by Cohen, R. B., Pereira, I. M., Garrido, M. M., Ferreira, B. V., Sousa, M. C.

“…Introduction Suicide in older people is a critical public and mental health issue which requires attention, given that the ageing population is increasing…”
Get full text

Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation by Posner, M.R., Norris, C.M., Wirth, L.J., Shin, D.M., Cullen, K.J., Winquist, E.W., Blajman, C.R., Mickiewicz, E.A., Frenette, G.P., Plinar, L.F., Cohen, R.B., Steinbrenner, L.M., Freue, J.M., Gorbunova, V.A., Tjulandin, S.A., Raez, L.E., Adkins, D.R., Tishler, R.B., Roessner, M.R., Haddad, R.I.

“…Locally advanced laryngeal and hypopharyngeal cancers (LHC) represent a group of cancers for which surgery, laryngectomy-free survival (LFS), overall survival…”
Get full text

A first-in-human study of the anti-α5β1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors by Mateo, J., Berlin, J., de Bono, J. S., Cohen, R. B., Keedy, V., Mugundu, G., Zhang, Lianglin, Abbattista, A., Davis, C., Gallo Stampino, C., Borghaei, H.

“…Purpose A first-in-human clinical trial of a fully human, Fc-engineered IgG1 monoclonal antibody targeting integrin α5β1 was conducted to evaluate…”
Get full text

Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours by Kozloff, M F, Martin, L P, Krzakowski, M, Samuel, T A, Rado, T A, Arriola, E, De Castro Carpeño, J, Herbst, R S, Tarazi, J, Kim, S, Rosbrook, B, Tortorici, M, Olszanski, A J, Cohen, R B

“…Background: This phase I dose-finding trial evaluated safety, efficacy and pharmacokinetics of axitinib, a potent and selective second-generation inhibitor of…”
Get full text

Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours by Martin, L P, Kozloff, M F, Herbst, R S, Samuel, T A, Kim, S, Rosbrook, B, Tortorici, M, Chen, Y, Tarazi, J, Olszanski, A J, Rado, T, Starr, A, Cohen, R B

“…Background: Axitinib, a potent and selective second-generation inhibitor of vascular endothelial growth factor receptors, enhanced the efficacy of chemotherapy…”
Get full text

A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies by von Mehren, M., Schilder, R.J., Cheng, J.D., Temmer, E., Cardoso, T.M., Renshaw, F.G., Bayever, E., Zannikos, P., Yuan, Z., Cohen, R.B.

“…To determine the maximum tolerated dose (MTD), safety, potential pharmacokinetic (PK) interactions, and effect on liver histology of trabectedin in combination…”
Get full text

The relationship between infliximab treatment and lymphoma in Crohn's disease by Bickston, Stephen J., Lichtenstein, Gary R., Arseneau, Kristen O., Cohen, Roger B., Cominelli, Fabio

“…The relationship between chronic inflammatory conditions and malignancy is complex. We describe the clinical course of 2 patients with Crohn's disease (CD) in…”
Get full text

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal by Ott, P.A., Piha-Paul, S.A., Munster, P., Pishvaian, M.J., van Brummelen, E.M.J., Cohen, R.B., Gomez-Roca, C., Ejadi, S., Stein, M., Chan, E., Simonelli, M., Morosky, A., Saraf, S., Emancipator, K., Koshiji, M., Bennouna, J.

“…Safety and efficacy of pembrolizumab, a humanized programmed death 1 monoclonal antibody, was assessed in KEYNOTE-028, a multicohort, phase Ib trial for…”
Get full text

Don’t Mono-crop the Movement: Toward a Cultural Ecology of Local Food by Cohen, B. R.

“…Over the past generation, advocates for healthier food and agriculture have drawn on the farm-to-fork trope to define spatial arrangements in the foodshed…”
Get full text

A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer by Jimeno, A., Shirai, K., Choi, M., Laskin, J., Kochenderfer, M., Spira, A., Cline-Burkhardt, V., Winquist, E., Hausman, D., Walker, L., Cohen, R.B.

“…This manuscript reports on a prospective, randomized study of cetuximab plus/minus a small molecule PI3K inhibitor (PX-866) targeting the protein product of…”
Get full text

Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors by Chiorean, E.G., Hurwitz, H.I., Cohen, R.B., Schwartz, J.D., Dalal, R.P., Fox, F.E., Gao, L., Sweeney, C.J.

“…Ramucirumab is a fully human immunoglobulin G1 monoclonal antibody receptor antagonist designed to block the ligand-binding site of vascular endothelial growth…”
Get full text

A phase I safety, pharmacological and biological study of the farnesyl protein transferase inhibitor, tipifarnib and capecitabine in advanced solid tumors by Gore, L, Holden, SN, Cohen, RB, Morrow, M, Pierson, AS, O'Bryant, CL, Persky, M, Gustafson, D, Mikule, C, Zhang, S, Palmer, PA, Eckhardt, SG

“…Background: To evaluate the toxicity and pharmacological and biological properties of the farnesyl protein transferase (FPTase) inhibitor, tipifarnib (R115777,…”
Get full text

Efficacy of the nanoparticle–drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I–IIa clinical trial by Keefe, S.M., Hoffman-Censits, J., Cohen, R.B., Mamtani, R., Heitjan, D., Eliasof, S., Nixon, A., Turnbull, B., Garmey, E.G., Gunnarsson, O., Waliki, M., Ciconte, J., Jayaraman, L., Senderowicz, A., Tellez, A.B., Hennessy, M., Piscitelli, A., Vaughn, D., Smith, A., Haas, N.B.

“…Anti-angiogenic therapies are effective in metastatic renal cell carcinoma (mRCC), but resistance is inevitable. A dual-inhibition strategy focused on…”
Get full text

Radiation induced angiosarcoma of the breast: outcomes from a retrospective case series by Cohen-Hallaleh, R B, Smith, H G, Smith, R C, Stamp, G F, Al-Muderis, O, Thway, K, Miah, A, Khabra, K, Judson, I, Jones, R, Benson, C, Hayes, A J

“…Radiation induced angiosarcoma (RIAS) of the breast is a rare and aggressive complication of radiotherapy. Due to the rarity of this disease, much of the…”
Get full text

The natural history of heterotopic ossification in patients who have fibrodysplasia ossificans progressiva. A study of forty-four patients by Cohen, R B, Hahn, G V, Tabas, J A, Peeper, J, Levitz, C L, Sando, A, Sando, N, Zasloff, M, Kaplan, F S

“…Forty-four patients who had fibrodysplasia ossificans progressiva responded by mail to a questionnaire regarding the age at the onset of heterotopic…”
Get full text

Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH ), a beta integrin antagonist, in patients with solid tumours by Cianfrocca, M E, Kimmel, K A, Gallo, J, Cardoso, T, Brown, M M, Hudes, G, Lewis, N, Weiner, L, Lam, G N, Brown, S C, Shaw, D E, Mazar, A P, Cohen, R B

“…To evaluate the toxicity, pharmacological and biological properties of ATN-161, a five -amino-acid peptide derived from the synergy region of fibronectin,…”
Get full text

Prospective Clinical Trial to Compare Vincristine and Vinblastine in a COP-Based Protocol for Lymphoma in Cats by Krick, E.L., Cohen, R.B., Gregor, T.P., Salah (Griessmayr), P.C., Sorenmo, K.U.

“…Background Current standard chemotherapy protocols for lymphoma in cats carry risks of gastrointestinal toxicity, which can decrease quality of life and…”
Get full text

Nucleotide regulation and characteristics of potassium channel opener binding to skeletal muscle membranes by Dickinson, K E, Bryson, C C, Cohen, R B, Rogers, L, Green, D W, Atwal, K S

“…[3H]P1075 binding to membrane preparations of rabbit skeletal muscle were observed in the presence of nucleotide triphosphates or diphosphates but not AMP,…”
Get more information

HIV-specific immunity following immunization with HIV synthetic envelope peptides in asymptomatic HIV-infected patients by PINTO, L. A, BERZOFSKY, J. A, NARA, P, SHEARER, G. M, YARCHOAN, R, FOWKE, K. R, LITTLE, R. F, MERCED-GALINDEZ, F, HUMPHREY, R, AHLERS, J, DUNLOP, N, COHEN, R. B, STEINBERG, S. M

“…A phase I trial was conducted to evaluate the safety and immunogenicity of an HIV synthetic peptide vaccine in HIV-seropositive individuals. The immunogens…”
Get full text